Revenue appeared in only one of the last ten quarters ($80.0M in 2024Q2), leaving operating losses of ~$19.9M in 2026Q2 driven by $12.4M of R&D, even as R&D was trimmed from $19.3M in 2024Q1 and roughly 70% of those savings were absorbed elsewhere in the cost base.
Fulcrum Therapeutics, Inc. (FULC) annual income statement — 9-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 |
|---|
| Sales/Revenue | 0 | 0 | 80M | 2.81M | 6.34M | 19.16M | 8.82M | 0 | 0 | 0 |
| Revenue Growth % | - | -100% | 2752.05% | -55.77% | -66.91% | 117.19% | - | - | - | - |
| Cost of Goods Sold | 554K | 1.39M | 63.39M | 71.8M | 76.78M | 69.7M | 59.04M | 2.05M | 1.34M | 715K |
| COGS % of Revenue | - | - | 79.23% | 2559.75% | 1210.69% | 363.73% | 669.18% | - | - | - |
| Gross Profit | -554K | -1.39M | 16.61M | -69M | -70.44M | -50.54M | -50.22M | -2.05M | -1.34M | -715K |
| Gross Margin % | - | - | 20.77% | -2459.75% | -1110.69% | -263.73% | -569.18% | - | - | - |
| Gross Profit Growth % | - | -108.37% | 124.08% | 2.05% | -39.38% | -0.64% | -2346.13% | -52.64% | -88.11% | - |
| Operating Expenses | 75.7M | 83.38M | 38.51M | 41.67M | 42.12M | 30.52M | 21.39M | 56.57M | 33.5M | 22.99M |
| OpEx % of Revenue | - | - | 48.14% | 1485.49% | 664.16% | 159.24% | 242.46% | - | - | - |
| Selling, General & Admin | 31.28M | 28.67M | 36.45M | 41.67M | 41.69M | 30.52M | 21.39M | 13.14M | 8.31M | 4.5M |
| SG&A % of Revenue | - | - | 45.56% | 1485.49% | 657.43% | 159.24% | 242.46% | - | - | - |
| Research & Development | 44.98M | 56.1M | 63.39M | 71.8M | 76.78M | 69.7M | 59.04M | 43.43M | 25.18M | 18.49M |
| R&D % of Revenue | - | - | 79.23% | 2559.75% | 1210.69% | 363.73% | 669.18% | - | - | - |
| Other Operating Expenses | -554K | -1.39M | -61.32M | -71.8M | -76.36M | -69.7M | -59.04M | 0 | 392K | 28K |
| Operating Income | -76.25M | -84.77M | -21.9M | -110.66M | -112.56M | -81.05M | -71.61M | -58.63M | -33.5M | -22.99M |
| Operating Margin % | - | - | -27.37% | -3945.24% | -1774.85% | -422.97% | -811.64% | - | - | - |
| Operating Income Growth % | - | -287.13% | 80.21% | 1.69% | -38.87% | -13.19% | -22.15% | -75.01% | -45.69% | - |
| EBITDA | -75.05M | -83.38M | -20.3M | -108.49M | -110.15M | -78.54M | -69.23M | -56.57M | -32.15M | -22.28M |
| EBITDA Margin % | - | - | -25.38% | -3867.81% | -1736.79% | -409.85% | -784.68% | - | - | - |
| EBITDA Growth % | 6.3% | -310.65% | 81.29% | 1.5% | -40.24% | -13.44% | -22.38% | -75.95% | -44.33% | - |
| D&A (Non-Cash Add-back) | 1.2M | 1.39M | 1.59M | 2.17M | 2.41M | 2.52M | 2.38M | 2.05M | 1.34M | 715K |
| EBIT | -70.6M | -74.88M | -19.83M | -97.33M | -112.13M | -80.85M | -71.61M | -82.68M | -33.5M | -22.99M |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 207K | 792K | 1.51M | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 207K | 792K | 1.51M | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -91K | 9.89M | 12.17M | 13.33M | 2.69M | 207K | 792K | -24.05M | 910K | 29K |
| Pretax Income | -76.34M | -74.88M | -9.72M | -97.33M | -109.87M | -80.85M | -70.82M | -82.68M | -32.59M | -22.96M |
| Pretax Margin % | - | - | -12.16% | -3470.05% | -1732.43% | -421.89% | -802.66% | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -76.34M | -74.88M | -9.72M | -97.33M | -109.87M | -80.85M | -70.82M | -82.68M | -32.59M | -22.96M |
| Net Margin % | - | - | -12.16% | -3470.05% | -1732.43% | -421.89% | -802.66% | - | - | - |
| Net Income Growth % | -7.35% | -669.97% | 90.01% | 11.41% | -35.9% | -14.16% | 14.34% | -153.7% | -41.91% | - |
| Net Income (Continuing) | -76.34M | -74.88M | -9.72M | -97.33M | -109.87M | -80.85M | -70.82M | -82.68M | -32.59M | -22.96M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.00 | -1.18 | -0.16 | -1.59 | -2.35 | -2.22 | -2.70 | -3.49 | -1.92 | -1.36 |
| EPS Growth % | 11.86% | -637.5% | 89.94% | 32.34% | -5.86% | 17.78% | 22.64% | -81.77% | -41.18% | - |
| EPS (Basic) | - | -1.18 | -0.16 | -1.59 | -2.35 | -2.22 | -2.70 | -3.49 | -1.92 | -1.36 |
| Diluted Shares Outstanding | 76.32M | 63.35M | 61.98M | 61.31M | 44.99M | 35.36M | 25.35M | 22.66M | 16.94M | 16.94M |
| Basic Shares Outstanding | 76.32M | 63.35M | 61.98M | 61.31M | 44.99M | 35.36M | 25.35M | 22.66M | 16.94M | 16.94M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying FULC stock.
For fiscal year 2025, Fulcrum Therapeutics, Inc. (FULC) reported total revenue of $0.0M.
Fulcrum Therapeutics, Inc. (FULC) reported a net loss of $74.9M for the fiscal year ending 2025.
Key Metrics
Top Statement Risk
Absence of recurring revenue
Metrics are mathematically derived from official filings.
Revenue Concentrated in One Quarter
According to Fulcrum's reported income statements, revenue appeared in only one of the ten quarters reviewed, $80.0M in 2024Q2, with the remaining periods printing no top line and mechanically generating -100.0% growth comparisons that obscure underlying business direction.
The pattern suggests the top line is driven by episodic transactions rather than a repeatable commercial stream, which means the -100.0% growth prints in 2024Q3, 2024Q4 and 2025Q2 largely reflect the arithmetic of lapping one outsized period rather than genuine demand destruction. For an analyst, the durability question therefore rests on whether any emerging revenue line can be identified in subsequent disclosures; absent that, the company's trajectory is better characterized as pre-revenue than growing or contracting.
R&D Consumes the Cost Structure
Research and development spending of $12.4M in 2026Q2 remains the largest expense line, exceeding SG&A of $7.5M by roughly 65 percent and driving the operating loss despite negligible cost of goods sold, based on Fulcrum's quarterly income statement disclosures.
R&D has stepped down from $19.3M in 2024Q1 to $12.4M in 2026Q2, a decline of about 36 percent that may indicate program prioritization or trial-stage timing rather than structural discipline, while SG&A has been comparatively sticky in the $6.8M to $10.2M band. The implication is that overhead is not scaling down in tandem with research spend, so further loss reduction would appear to depend on the durability of the R&D cuts rather than on administrative efficiency.
2024Q2 Milestone Distorts the Baseline
The 2024Q2 quarter stands alone, delivering $52.5M of operating income and $0.87 diluted EPS on $80.0M of revenue versus operating losses near $20M in every other period shown, a swing that appears to define the entire ten-quarter history as reported in Fulcrum's filings.
The 78.4% gross margin and 65.6% operating margin in that quarter imply licensing-like economics rather than product economics, and the fact that net income of $55.4M exceeded operating income suggests the period also carried meaningful non-operating gains. Every subsequent comparison is anchored to this anomaly, so normalized profitability should be assessed against the recurring $19M to $27M quarterly operating losses rather than the headline margins.
Non-Operating Swings Cloud Net Losses
Stock-based compensation of $2.5M to $4.3M per quarter represents a persistent drag on reported losses, while net income of $55.4M in 2024Q2 exceeded operating income of $52.5M and 2026Q2's $26.2M loss exceeded its $19.9M operating loss, according to Fulcrum's reported figures.
The gap between operating and net results flips direction across periods, which suggests material non-operating items such as investment marks, interest income or one-off charges are moving through the bottom line and warrant further investigation before the net loss trend is treated as operational. SBC at roughly $2.5M to $4.3M per quarter appears meaningful relative to a recurring net loss of approximately $17M to $26M, so cash-burn economics may differ from reported EPS erosion.
Windfall Recurrence Anchors the Bear Case
Operating expenses have held near $20M per quarter while revenue was absent in nine of ten periods, suggesting the 2024Q2 windfall may prove non-recurring and that the loss trajectory, not the 65.6% peak operating margin, is the operative trend.
A short-seller would likely focus on gross profit being negative in seven of the ten quarters, including -$14.3M in 2025Q3 and -$13.4M in 2025Q1, which implies cost of goods continues to be recognized without corresponding revenue and compresses any path to self-funded operations. The strongest counter-narrative is that peers such as Arrowhead and Amicus post 200%+ and 20% growth on real revenue bases, whereas FULC's implied fundamentals rest on a single quarter, leaving the equity exposed if no follow-on transaction materializes.
Losses Resist Scaling as Spend Falls
Despite R&D declining from $19.3M in 2024Q1 to $12.4M in 2026Q2, the operating loss only narrowed to $19.9M from $29.8M, meaning roughly 70 percent of the research savings were absorbed elsewhere in the cost base.
SG&A rose from $7.7M in 2024Q4 to $8.1M in 2026Q1 while gross profit remained negative, so the expected operating leverage from a leaner pipeline has not fully transmitted to the operating line. Investors should monitor whether the 2026Q1-to-2026Q2 improvement in operating loss, from $22.2M to $19.9M, marks the start of a durable trend or merely quarterly expense phasing.